Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Like mutations with loss of function in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, inhibitors of PCSK9 (PCSK9i) may potentially favor the manifestation of diabetes. RESEARCH DESIGN AND METHODS: A meta-analysis of phase 2/3 randomized clinical trials (RCTs) assessed PCSK9i versus placebo in the primary hypercholesterolemia setting. Statins and ezetimibe were used in 98.4% of these studies and balanced between PCSK9i and placebo. We calculated relative risks (RRs) and 95% CIs using random- and fixed-effect models. RESULTS: We included 68,123 participants (20 RCTs) with median follow-up of 78 weeks. PCSK9i increased fasting blood glucose (weighted mean difference 1.88 mg/dL [95% CI 0.91–2.68]; I2 = 0%; P < 0.001) and HbA1c (0.032% [0.011–0.050]; I2 = 15.5%; P < 0.001) when compared with placebo. This effect was not sufficient to increase incidence of diabetes (RR 1.04 [0.96–1.13]; I2 = 0%; P = 0.427). Exploratory meta-regression analyses indicated an association between the increased risk of diabetes and the potency (P = 0.029) and duration (P = 0.026) of PCSK9i treatment. CONCLUSIONS: In the short term, PCSK9i therapy favors a small but significant increase in plasma glycemia and HbA1c.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, a new class of drugs, PCSK9 inhibitors, has become available that targets a protein (PCSK9) involved in the control of the LDLR [280].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [280]
Citations
Cites
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436 · cited 1×
“In linewith our findings, ameta-analysis including 91,140 patients followed during ;4 years found a 9% increased risk for incident diabetes with statins (20).”
BackgroundEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Nicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16951 · Cited by 1,178
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701488 · Cited by 624
Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 588
Kastelein, J. J. P., Ginsberg, H. N., Langslet, G., Hovingh, G. K., Ceska, R., Dufour, R., Blom, D., Civeira, F., Krempf, M., Lorenzato, C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv370 · Cited by 533
Raal, F., Scott, R., Somaratne, R., Bridges, I., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 508
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., & Stein, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201832 · Cited by 469
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Using Mendelian Randomization to Improve the Design of Randomized Trials
Ference, B. A., Holmes, M. V., & Smith, G. D. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a040980 · Cited by 338
“This findingwas confirmed in some but not all randomized trials (Baigent et al. 2010; Sabatine et al. 2017; de Carvalho et al. 2018).”
ResultDa Dalt, L., Ruscica, M., Bonacina, F., Balzarotti, G., Dhyani, A., Di Cairano, E., Baragetti, A., Arnaboldi, L., De Metrio, S., Pellegatta, F., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy357 · Cited by 209
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Lipid lowering and Alzheimer disease risk: A mendelian randomization study
Williams, D. M., Finan, C., Schmidt, A. F., Burgess, S., & Hingorani, A. D. (2020) · Annals of Neurology · doi:10.1002/ana.25642 · Cited by 157
Genomic insights into the causes of type 2 diabetes
Langenberg, C., & Lotta, L. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31132-2 · Cited by 149
Cholesterol metabolism, pancreatic β-cell function and diabetes
Perego, C., Da Dalt, L., Pirillo, A., Galli, A., Catapano, A. L., & Norata, G. D. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.04.012 · Cited by 135
Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment
Gieroba, B., Kryska, A., & Sroka‐Bartnicka, A. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102037 · Cited by 209
“Treatment with anti-PCSK9 monoclonal antibodies (MAbs) can reduce plasma LDL cholesterol (LDL-C) levels by 50 – 60 % [194].”
Lovegrove, C. E., Howles, S., Furniss, D., & Holmes, M. V. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae136 · Cited by 95
Khan, S. U., Rahman, H., Okunrintemi, V., Riaz, H., Khan, M. S., Sattur, S., Kaluski, E., Lincoff, A. M., Martin, S. S., & Blaha, M. J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011581 · Cited by 70
Cupido, A. J., Reeskamp, L. F., Hingorani, A. D., Finan, C., Asselbergs, F. W., Hovingh, G. K., & Schmidt, A. F. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2333 · Cited by 68
Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism
Xiao, X., Luo, Y., & Peng, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.879355 · Cited by 70
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Lorenzatti, A. J., & Toth, P. P. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.06 · Cited by 72
Cao, Y., Liu, H., Dong, Q., Li, S., & Li, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13235 · Cited by 61
“Previous pooled analyses showed that PCSK9-mAbs had no effect on NODM or glucose homeostasis(16,17); however, a meta-analysis that included bococizumab, a non-fully humanized monoclonal antibody and finally withdrawn from the future clinical research and application, reported that PCSK9-mAbs significantly increased FP…”
ResultThe Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus
Bonilha, I., Hajduch, É., Luchiari, B., Nadruz, W., Goff, W. L., & Sposito, A. C. (2021) · Metabolites · doi:10.3390/metabo11120807 · Cited by 62
Self-citationDysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis
Liu, Y., Zhao, Y., Shukha, Y., Lu, H., Wang, L., Liu, Z., Liu, C., Zhao, Y., Wang, H. H., Zhao, G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109420 · Cited by 52
Caselli, C., Del Turco, S., Ragusa, R., Lorenzoni, V., De Graaf, M., Basta, G., Scholte, A., De Caterina, R., & Neglia, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0949-3 · Cited by 50
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Schmidt, A. F., Holmes, M. V., Preiss, D., Swerdlow, D. I., Denaxas, S., Fatemifar, G., Faraway, R., Finan, C., Lumbers, R. T., Henry, A., et al. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1187-z · Cited by 42
Low-Density Lipoprotein Cholesterol Is Associated With Insulin Secretion
Dannecker, C., Wagner, R. J., Peter, A., Hummel, J., Vosseler, A., Häring, H., Fritsche, A., Birkenfeld, A. L., Stefan, N., & Heni, M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab147 · Cited by 43
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
Carugo, S., Sirtori, C. R., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01074-y · Cited by 45
Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study
Goldman, A., Raschi, E., Cukierman‐Yaffe, T., Dankner, R. S., Shouval, R., Shechter, M., Ben‐Zvi, I., Gerstein, H. C., & Maor, E. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab209 · Cited by 38
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024) · Drugs · doi:10.1007/s40265-024-01995-9 · Cited by 38
“One recent meta-analysis [78] indicated a slight increase of HbA1c after PCSK9 inhibition, whereas another meta-analysis [79] reported no effect on new-onset diabetes or glucose metabolism.”
ResultCirculating PCSK9 levels are not associated with the conversion to type 2 diabetes
Ramin‐Mangata, S., Wargny, M., Pichelin, M., May, C. L., Thedrez, A., Blanchard, V., Nativel, B., Santos, R. D., Benseñor, I. M., Lotufo, P. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.11.027 · Cited by 35
PCSK9 inhibition: from effectiveness to cost-effectiveness
Mercep, I., Strikic, D., Hrabac, P., Pecin, I., & Reiner, Ž. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1339487 · Cited by 31
Shi, J., Zhang, W., Niu, Y., Lin, N., Li, X., Zhang, H., Hu, R., Ning, G., Fan, J., Qin, L., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01185-3 · Cited by 34
Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism
González-Lleó, A. M., Sánchez-Hernández, R. M., Boronat, M., & Wägner, A. M. (2022) · Nutrients · doi:10.3390/nu14071503 · Cited by 41
An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
Choi, H. D., & Kim, J. H. (2023) · Cardiovascular Therapeutics · doi:10.1155/2023/7362551 · Cited by 33
Ginsberg, H. N., Farnier, M., Robinson, J. G., Cannon, C. P., Sattar, N. A., Baccara‐Dinet, M. T., Letierce, A., Bujas‐Bobanovic, M., Louie, M. J., & Colhoun, H. M. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0439-8 · Cited by 28
Chiu, S., Pratt, C. M., Feinn, R., & Chatterjee, S. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420924983 · Cited by 27
“5 years.(17) Another study evaluating patients already diagnosed with diabetes mellitus concluded that PCSK9i do not affect glucose metabolism.”
BackgroundImpact of PCSK9 inhibitors in glycaemic control and new-onset diabetes
González-Lleó, A. M., Sánchez-Hernández, R. M., Plana, N., Ibarretxe, D., Rehues, P., Ribalta, J., Llop, D., Wägner, A. M., Masana, L., & Boronat, M. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02077-y · Cited by 23
“However, Mendelian randomisation studies [7, 9], some meta-analyses [14, 15] and real-life studies [16] published in recent years have found a slight deterioration in glycaemic control among users of these drugs.”
BackgroundThe Genetic Link Between Diabetes and Atherosclerosis
Ross, S. A., Gerstein, H. C., & Paré, G. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.01.016 · Cited by 24
Benea, C., Turner, K. A., Roseman, M., Bero, L. A., Lexchin, J., Turner, E. H., & Thombs, B. D. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01318-5 · Cited by 27
Faraj, M. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20190124 · Cited by 25
Chen, Q., Wu, G., Li, C., Qin, X., Liu, R., & Zhang, M. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00386-w · Cited by 22
Kim, E. J., & Wierzbicki, A. S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320924569 · Cited by 22
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Filippatos, T. D., Christopoulou, E. C., & Elisaf, M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000523 · Cited by 22
PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice
Ferrari, F., Stein, R., Motta, M. T., & Moriguchi, E. H. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190029 · Cited by 26
2022 Saudi Guidelines for the Management of Dyslipidemia
Alrahimi, J. S., AlSaif, S. M., Alasnag, M. A., Awan, Z. A., Almutairi, F., Mudaiheem, H. Y. A., Gencer, B., Catapano, A. L., Mach, F., & Tash, A. A. (2023) · Heart Views · doi:10.4103/heartviews.heartviews_102_22 · Cited by 28
“[77,107] Chronic kidney disease CKD stage 3 is considered high, and stage 4–5 is considered very high risk.”
The Cross-Talk Between the Peripheral and Brain Cholesterol Metabolisms
Săvulescu-Fiedler, I., Dorobantu-Lungu, L.-R., Dragosloveanu, Ş., Benea, S. N., Dragosloveanu, C. D. M., Căruntu, A., Scheau, A.-E., Căruntu, C., & Scheau, C. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47020115 · Cited by 25
“Overall, the use of Nar in lowering cholesterol levels may represent an effective and novel approach that is not burdened by the adverse effects related to statins or PCSK9i.”
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Chen, T., Wang, Z., Xie, J., Xiao, S., Li, W., & Liu, N. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.033 · Cited by 20
Unexplained reciprocal regulation of diabetes and lipoproteins
Higuchi, S., Izquierdo, M. C., & Haeusler, R. A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000521 · Cited by 20
Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials
Stoekenbroek, R. M., & Kastelein, J. J. P. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000517 · Cited by 14
PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations
Holmes, M. V., Kartsonaki, C., Boxall, R., Lin, K., Reeve, N. F., Yu, C., Lv, J., Bennett, D., Hill, M., Yang, L., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae009 · Cited by 14
“7 As with statins, 8 confirmation (or refutation) of any excess risk of diabetes will likely require meta-analysis of multiple large trials with patients treated and followed up for longer durations.”
Molecular and cellular biology of PCSK9: impact on glucose homeostasis
Tcheoubi, S. E. R., Akpovi, C. D., Coppée, F., Declèves, A., Laurent, S., Agbangla, C., & Burtéa, C. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2092622 · Cited by 13
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Athyros, V. G., Doumas, M. N., & Karagiannis, A. I. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190426162746 · Cited by 13
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
Marouf, B. H., Iqbal, Z., Mohamad, J. B., Bashir, B., Schofield, J. D., Syed, A. A., Kilpatrick, E. S., Stefanutti, C., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.12.005 · Cited by 12
Insight into the role of PCSK9 in glucose metabolism
Xu, J., Wang, T., Shu, H., Shi, S., Tao, L., & Li, J. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117444 · Cited by 11
Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?
Noto, D., Giammanco, A., Barbagallo, C. M., Cefalu, A. B., & Averna, M. R. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy144 · Cited by 12
Association between serum PCSK9 and coronary heart disease in patients with type 2 diabetes mellitus
Huang, J., Gu, J.-X., Wang, K., Zhang, A., Hong, T.-T., Li, S.-S., Yao, X., Yang, M. J., Yin, Y., Zhang, N., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01238-z · Cited by 12
Geranylgeranyl isoprenoids and hepatic Rap1a regulate basal and statin-induced expression of PCSK9
Wang, Y., Tinsley, B., Spolitu, S., Zadroga, J. A., Agarwal, H., Sarecha, A. K., & Özcan, L. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100515 · Cited by 10
Statins and diabetes mellitus progression: a fly in the ointment?
Katsiki, N., & Mikhailidis, D. P. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00612-z · Cited by 10
Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy
Beltran, R. A., Zemeir, K., Kimberling, C. R., Kneer, M. S., Mifflin, M. D., & Broderick, T. L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192416899 · Cited by 10
Shi, W., Li, J., Bao, K., Chen, M., & Liu, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10061429 · Cited by 10
The Pleiotropic Effects of Statins in Endocrine Disorders
Cruz, J. A. D. L., Mihos, C. G., Horvath, S. A., & Santana, O. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190329115003 · Cited by 9
Brandts, J., & Müller‐Wieland, D. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0802-x · Cited by 10
PCSK9 in diabetes: sweet, bitter or sour?
Paneni, F., & Costantino, S. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy432 · Cited by 9
Lu, F., Li, E., & Yang, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19371 · Cited by 9
“Although these changes are insufficient to induce diabetes, the risk of NODM was found to be positively associated with reduced LDL-C levels and treatment duration [82].”
BackgroundGonzález-Lleó, A. M., Brito‐Casillas, Y., Martín-Santana, V., Gil-Quintana, Y., Tugores, A., Scicali, R., Riaño, M., Hernández-Baraza, L., Jiménez‐Monzón, R., Girona, J., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02857-8 · Cited by 8
Sánchez-Hernández, R. M., González-Lleó, A. M., Tugores, A., Brito‐Casillas, Y., Civeira, F., Boronat, M., & Wägner, A. M. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.010 · Cited by 7
Lipids: a personal view of the past decade
Katsiki, N., & Mikhailidis, D. P. (2018) · HORMONES · doi:10.1007/s42000-018-0058-9 · Cited by 6
The biological relevance of PCSK9: when less is better…
Mbikay, M., & Chrétien, M. (2022) · Biochemistry and Cell Biology · doi:10.1139/bcb-2021-0540 · Cited by 7
Cao, Y., & Li, J. (2018) · Diabetes Care · doi:10.2337/dc17-2563 · Cited by 6
“(1) covered patients with diabetes at baseline, which might result in serious bias during the meta-analysis according”
BackgroundTime to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease
Li, L., Huang, C., Liu, W., Li, J., Geru, A., Chen, X., Jiang, S., Fang, Y., Foo, R., Chan, M. Y., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.09.014 · Cited by 6
de Carvalho, L. S. F., Campos‐Staffico, A. M., & Sposito, A. C. (2018) · Diabetes Care · doi:10.2337/dci17-0069 · Cited by 5
“Cao and Li for their comment (1) on our article (2).”
BackgroundSelf-citationRivera, F. B., Cha, S. W., Magalong, J. V., Bantayan, N. R. B., Cruz, L. L. A., Arias-Aguirre, E., Aguirre, Z., Varona, M. C., Co, E. M. F., Lumbang, G. N. O., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2363971 · Cited by 5
“However, a 2017 meta-analysis showed a small but significant increase in glycemia and HbA1c levels after a PCSK9i use 53,54 .”
BackgroundINNOVATIVE WAYS OF IMPROVING MEDICINE, PSYCHOLOGY AND BIOLOGY
Vladlenov, D., Khrebtii, H. I., Коваль, Г., Вакаров, О. С., Карбованець, О. І., Голомб, Л., Петросова, В. І., Руснак, І., Кулачек, В., Кулачек, Я., et al. (2023) · Іnternational Science Group eBooks · doi:10.46299/isg.2023.mono.med.2 · Cited by 41
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Pancreatic PCSK9 and its involvement in diabetes
Kockx, M., & Kritharides, L. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.06.37 · Cited by 4
PCSK9 inhibitors and diabetes mellitus
Vohnout, B., Lisičanová, J., & Havranová, A. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.170 · Cited by 4
Sánchez-Hernández, R. M., González-Lleó, A. M., Tugores, A., Brito‐Casillas, Y., Civeira, F., Boronat, M., & Wägner, A. M. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.08.003 · Cited by 4
Hamad, M. A., Muhammad, J. S., Rah, B., Hasan, H. A., Taneera, J., Soofi, A., & Awadallah, S. M. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300107 · Cited by 3
Alraddadi, S. I., Almodaimegh, H., Kharbosh, A., Alharbi, H., Fathelrahman, A. I., Alsheikh, M. Y., & Alfehaid, L. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01587-x · Cited by 4
Further options for treating lipids in people with diabetes: targeting LDL ‐cholesterol and beyond
Wierzbicki, A. S. (2018) · Diabetic Medicine · doi:10.1111/dme.13667 · Cited by 5
Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials
Shukla, A. K., & Mehani, R. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_406_19 · Cited by 3
Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study
Moffa, S., Mezza, T., Ferraro, P. M., Giuseppe, G. D., CEFALO, C. M. A., Cinti, F., Impronta, F., Capece, U., Ciccarelli, G., Mari, A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1124116 · Cited by 4
Lu, J., Liu, Y., Wang, Z., Zhou, K., Pan, Y., Zhong, S., & Jiang, G. (2024) · JACC Asia · doi:10.1016/j.jacasi.2024.07.011 · Cited by 4
Faraj, M. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30042-2 · Cited by 6
Lin, J., HSU, C., Lo, S., Nigam, N., Shenoi, M., Tu, Y.-F., BHANDERI, H., Chen, C., Su, Y., Chang, H., et al. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70188 · Cited by 2
Association between the rs615563 variant of PCSK9 gene and circulating lipids and Type 2 diabetes
Jazdani, S. T., Shahbazian, H. B., Cheraghian, B., Jalali, M. T., & Mohammadtaghvaei, N. (2021) · BMC Research Notes · doi:10.1186/s13104-021-05723-4 · Cited by 2
“For example, a study has reported pharmacological treatments with PCSK9 inhibitors in patients with primary hypercholesterolemia resulted in increased fasting glucose levels compared to placebo but with no increase in the incidence of diabetes [14].”
Low cholesterol syndrome and drug development
Handhle, A., Viljoen, A., Ramachandran, R., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000745 · Cited by 3
Skutki hamowania funkcji PCSK9 w obrębie wybranych tkanek *
Maligłówka, M., Bułdak, Ł., Okopień, B., & Bołdys, A. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.9127 · Cited by 2
Precision Medicine Approaches for Management of Type 2 Diabetes
Chen, D., Fulcher, J., SCOTT, E. S., & Jenkins, A. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_1 · Cited by 3
Cardiovascular disease and its association with insulin resistance and cholesterol
Ali, N. M., Diamond, D. M., & Rice, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821617-0.00016-4 · Cited by 3
Farnier, M. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.01.02 · Cited by 2
Serhiyenko, V. A., & Serhiyenko, A. A. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.1.2023.1242 · Cited by 1
Zhang, R., Wang, Y., Peng, Y., Zhao, J., & Zhang, Z. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1117143 · Cited by 2
Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study
Chen, Z., Triatin, R. D., Luo, L., Snieder, H., Schmidt, A. F., Ditmarsch, M., Kastelein, J. J. P., Dullaart, R. P. F., Kuivenhoven, J. A., & Thio, C. H. L. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03209-w · Cited by 1
Therapie der diabetischen Dyslipidämie
Brandts, J., & Lebherz, C. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0362-7 · Cited by 1
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibition: A Lipocrinologic Review.
Kalra, S. (2018) · PubMed · Cited by 1
Inhibiteurs PCSK9 en pratique clinique : données et interrogations
Vergès, B. L., Dubois, C., & Legris, P. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.010 · Cited by 1
Mäkelä, K. A., Jokelainen, J. J., Stenbäck, V., AUVINEN, J. P., Järvelin, M., Tulppo, M. P., Leppäluoto, J., Keinanen-Kiukaanniemi, S. M., & Herzig, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050994 · Cited by 1
“The use of statins has been linked to increased risk of T2D [41], but PCSK9 inhibitors have also been implicated in the development of diabetes [15,16] and further long-term observations are required.”
BackgroundGu, J.-X., Wang, K., Zhang, A., Yin, Y., Li, S.-S., Zhang, N., Qin, L., Wang, C.-Y., Pei, L., Jia, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-93750-7 · Cited by 1
Nashawi, M., Sheikh, O., Mir, M., Te, T., & CHILTON, R. J. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000204 · Cited by 1
Müller‐Wieland, D., Brandts, J., Marx, N., & Schütt, K. S. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0394-z
Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes
Müller‐Wieland, D., & Parhofer, K. G. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-124740
Does the treatment with PCSK9 inhibitors increase the risk of type 2 diabetes?
(2019) · Archives of the Balkan Medical Union · doi:10.31688/abmu.2019.54.1.7
Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes
Müller‐Wieland, D., & Parhofer, K. G. (2019) · Gefäßmedizin Scan - Zeitschrift für Angiologie Gefäßchirurgie diagnostische und interventionelle Radiologie · doi:10.1055/a-0858-3922
The role of PCSK9 in glomerular lipid accumulation and renal injury in diabetic kidney disease
윤창연 (2019) · YUHSpace (Yonsei University Medical Library)
Metadata
- Authors
- de Carvalho, L. S. F., Campos, A. M., & Sposito, A. C.
- Affiliations
- Cardiology Department, State University of Campinas, Campinas, São Paulo, Brazil
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-11-27
- Volume
- 41
- Issue
- 2
- Pages
- 364-367
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2769398456
- Cited by
- 121
- References
- 24
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 18 · 2023: 16 · 2022: 10 · 2021: 14 · 2020: 16 · 2019: 19 · 2018: 21
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9 inhibitors, type 2 diabetes, fasting blood glucose, HbA1c, hypercholesterolemia, statins, ezetimibe, treatment duration
- MeSH terms
- Ezetimibe, Proprotein Convertase 9, PCSK9 Inhibitors, Blood Glucose, Diabetes Mellitus, Type 2, Enzyme Inhibitors, Humans, Hypercholesterolemia, Cholesterol, LDL, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.